Main Menu

Qualifications

Chartered Statistician, Royal Statistical Society, UK.

Ph.D. in Statistics, Department of Statistics, University of Glasgow.

Postgraduate module in Teaching, Learning and Assessment in Higher Education, Teaching and Learning Service, University of Glasgow.

Master in Science (Mathematics and Statistics) First Class Honours, University of Glasgow.

Awards, Prizes or Honours

Council of Vice Chancellors and Principals Overseas Research Scholarship, Committee of Vice-Chancellors and Principals, U.K., 1999.

University of Glasgow Postgraduate Scholarship, University of Glasgow, 1999.

Most Outstanding Statistics Graduate at University of Glasgow, William M. Mercer Ltd, 1999.

Editorial Boards

Associate Editor for Trials, 2020.

External Committees

NCRI Head & Neck Study Group, Appointed Member, National Cancer Research Institute (NCRI), 2016-present.

NCRI Skin Cancer Study Group, Appointed Member, National Cancer Research Institute (NCRI), 2017-present.

NCRI CTRad Workstream 3 Randomised Phase III, Appointed Member, National Cancer Research Institute (NCRI), 2015-2018.

Adaptive Designs CONSORT Extension, Expert Panel Member, Adaptive Designs CONSORT Extension, 2016-2019.

NCRI Non-melanoma Skin Cancer subgroup, Member, National Cancer Research Institute (NCRI), 2014-2018.

TMRP Stratified Medicine Working Group, Joint Lead, MRC-NIHR Trials Methodology Research Partnership, 2019-present.

TMRP Adaptive Design Working Group, Member, MRC-NIHR Trials Methodology Research Partnership (TMRP), 2013-present.

NIHR Early Phase Clinical Trials, Co-Chair (from 2019), Committee Member (2015-2019), NIHR Statistics Group, 2015-present.

UKCRC Registered Clinical Trials Unit Statisticians’ Operational Group, Senior Statistics Representative, UKCRC Registered Clinical Trials Unit, 2015-2019.

RDS West Midlands, Statistical Advisor, RDS West Midlands, 2015-2019.

Data Monitoring Committee, Independent Statistician, DANTE A randomised phase III trial to evaluate the Duration of ANti-PD1 monoclonal antibody Treatment in patients with metastatic mElanoma

Data Monitoring Committee, Independent Statistician, Early Phase NEPHSTROM Clinical trial “Novel Stromal Cell Therapy for Diabetic Kidney Disease”

Data Monitoring Committee, Independent Statistician, ORCA-2: a phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck

Data Monitoring Committee, Independent Statistician, Chariot: A phase I dose escalation safety study combining the ATR inhibitor M6620 with chemoradiotherapy in oesophageal cancer & other solid cancers using time to event continual reassessment method

Cancer Research UK Clinical Research Committee, Funding panel member, Cancer Research UK, 2018-present.

Cancer Research UK Clinical Expert Review Panel (CERP), Co-opted funding panel member, Cancer Research UK Clinical Expert Review Panel (CERP), 2018-2019.

MRC Confidence in Concept, Funding panel member, MRC Confidence in Concept, University of Birmingham, 2017-2019.

MRC Experimental Medicine Panel, Full funding panel member (from 2021); Interim member (2020), Medical Research Council (MRC) Experimental Medicine, 2020.

College of Experts for the UKRI-DHSC COVID-19 rapid research funding initiative, Member of the College of Experts, UKRI-DHSC COVID-19 rapid research funding initiative, 2020.

Rare Disease subgroup (TMRP Stratified Medicine Working Group), Lead, MRC-NIHR Trials Methodology Research Partnership (TMRP), Jan 2020.

ESMO Targeted Anticancer Therapies Congress, Congress Scientific Committee member, ESMO, 2020.

Athena SWAN, Steering Group member, ICR, 2020.

TMRP Statistical Analysis Working Group, Core Committee member, MRC-NIHR Trials Methodology Reserach Partnership, 2019.

Data Monitoring Committee, DMEC chair and statistician, FITNEss: Phase III UK-MRA Myeloma XIV study. Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I)

Data Monitoring Committee, Independent Statistician, • Catalyst: A randomised phase II proof of principle multi-arm multi-stage trial designed to guide selection of interventions for phase III trials in hospitalised patients with COVID-19 infection

Data Monitoring Committee, Statistical IDMC Mentor, PRIMUS004: A multi-arm non-comparative signal seeking phase II platform trial of biomarker-directed novel second-line treatments in metastatic pancreatic cancer